A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Phase 1/2
77
about 8.2 years
18+
1 site in CA
What this study is about
This trial is testing a cancer vaccine called Labvax 3(22)-23, along with GM-CSF alone or combined with pembrolizumab, to treat adenocarcinoma that has spread. The goal is to see if this treatment can help the body's immune system fight against the cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Antineoplastic Vaccine
- 2.Receive Pembrolizumab
- 3.Receive Sargramostim
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
vaccine, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), sargramostim
injection, infusion
Primary: Phase 1: Adverse events (AEs), Phase 1: Dose-limiting toxicities (DLT), Phase 2: Objective response rate (ORR)
Secondary: Phase 1: Objective response rate (ORR), Phase 2: Adverse events (AEs), Phase 2: Dose-limiting toxicities (DLT), Phase 2: Overall survival (OS), Phase 2: Progression free survival (PFS)
Oncology